PMID- 16188305
OWN - NLM
STAT- MEDLINE
DCOM- 20060302
LR  - 20240312
IS  - 0091-3057 (Print)
IS  - 0091-3057 (Linking)
VI  - 82
IP  - 2
DP  - 2005 Oct
TI  - Reduced startle gating after D1 blockade: effects of concurrent D2 blockade.
PG  - 293-9
AB  - BACKGROUND: Prefrontal D1 systems have been implicated in the regulation of 
      working memory and in the pathophysiology of schizophrenia. D1 hypofunction might 
      contribute to reduced sensorimotor gating in schizophrenia patients since D1 
      activity in the medial prefrontal cortex (MPFC) regulates prepulse inhibition of 
      startle (PPI) in animal models. We studied the neurochemical basis for the D1 
      regulation of PPI in rats. METHODS: PPI to weak (1-5 dB over background) 
      prepulses was measured after systemic or intra-MPFC administration of the D1 
      antagonist, SCH 23390, in rats pretreated systemically with the D2 antagonist, 
      haloperidol (vehicle or 0.1 mg/kg). RESULTS: After vehicle pretreatment, systemic 
      and intra-MPFC SCH 23390 disrupted PPI produced by weak prepulses. This effect 
      was not significantly opposed by pretreatment with haloperidol (0.1 mg/kg). In 
      contrast, the PPI-disruptive effects of the DA agonist amphetamine were 
      significantly opposed by this dose of haloperidol. CONCLUSIONS: D1 blockade 
      reduces PPI, but this effect does not appear to be mediated entirely via 
      increased dopamine transmission at D2 receptors.
FAU - Swerdlow, Neal R
AU  - Swerdlow NR
AD  - Department of Psychiatry, UCSD School of Medicine, 9500 Gilman Dr., La Jolla, CA 
      92037-0804, USA. nswerdlow@ucsd.edu
FAU - Shoemaker, Jody M
AU  - Shoemaker JM
FAU - Bongiovanni, Michele J
AU  - Bongiovanni MJ
FAU - Neary, Alaina C
AU  - Neary AC
FAU - Tochen, Laura S
AU  - Tochen LS
FAU - Saint Marie, Richard L
AU  - Saint Marie RL
LA  - eng
GR  - K02 MH001436/MH/NIMH NIH HHS/United States
GR  - R01 MH053484/MH/NIMH NIH HHS/United States
GR  - MH01436/MH/NIMH NIH HHS/United States
GR  - MH53484/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20050926
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - 0 (Benzazepines)
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Dopamine D2 Receptor Antagonists)
RN  - 0 (Dopamine Uptake Inhibitors)
RN  - 0 (Receptors, Dopamine D1)
RN  - CK833KGX7E (Amphetamine)
RN  - J6292F8L3D (Haloperidol)
SB  - IM
MH  - Amphetamine/administration & dosage/pharmacology
MH  - Animals
MH  - Benzazepines/administration & dosage/pharmacology
MH  - Depression, Chemical
MH  - Dopamine Antagonists/administration & dosage/*pharmacology
MH  - *Dopamine D2 Receptor Antagonists
MH  - Dopamine Uptake Inhibitors/administration & dosage/pharmacology
MH  - Haloperidol/administration & dosage/pharmacology
MH  - Injections
MH  - Male
MH  - Prefrontal Cortex/physiology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Dopamine D1/*antagonists & inhibitors
MH  - Reflex, Startle/*drug effects
PMC - PMC1364453
MID - NIHMS6729
EDAT- 2005/09/29 09:00
MHDA- 2006/03/03 09:00
PMCR- 2008/01/25
CRDT- 2005/09/29 09:00
PHST- 2005/06/14 00:00 [received]
PHST- 2005/08/19 00:00 [revised]
PHST- 2005/08/24 00:00 [accepted]
PHST- 2005/09/29 09:00 [pubmed]
PHST- 2006/03/03 09:00 [medline]
PHST- 2005/09/29 09:00 [entrez]
PHST- 2008/01/25 00:00 [pmc-release]
AID - S0091-3057(05)00297-2 [pii]
AID - 10.1016/j.pbb.2005.08.018 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 2005 Oct;82(2):293-9. doi: 10.1016/j.pbb.2005.08.018. 
      Epub 2005 Sep 26.